Osteochondrodysplasias: Clinical Trials

83 trials for Osteochondrodysplasias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 15 terminated, 11 active not recruiting, 11 recruiting. 83 Phase 2, 12 Phase 1, 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 283Completed 33, Terminated 15, Active not recruiting 11, Recruiting 11, Unknown 5, Enrolling by invitation 4, Not yet recruiting 2, Withdrawn 2
Phase 112Terminated 3, Active not recruiting 2, Completed 2, Not yet recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 312Completed 4, Recruiting 3, Enrolling by invitation 2, Active not recruiting 1, Terminated 1, Unknown 1

Follow Osteochondrodysplasias: new trials by email Literature Review of Osteochondrodysplasias trials Research Report on Osteochondrodysplasias

Trials (filtered) newest first · largest first

All 83 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Phase 1 / Phase 2Not yet recruitingEmory University122027-01-012026-05-08
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2RecruitingBicara Therapeutics1602026-09-012026-10-13
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
AGA2115 - Osteogenesis Imperfecta (OI)
Phase 2RecruitingAngitia Biopharmaceuticals Guangzhou Limited482026-07-142026-09-22
Gene-Modified Stem Cell Therapy for Children With Autosomal Recessive Osteopetrosis (ARO)
FT024 - Osteopetrosis
Phase 1 / Phase 2RecruitingFondazione Telethon82026-06-202026-06-24
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Infigratinib - Hypochondroplasia
Phase 2Enrolling by invitationQED Therapeutics, a BridgeBio company1352026-04-232026-08-26
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia
Phase 2 / Phase 3RecruitingBioMarin Pharmaceutical1602026-04-202026-10-22
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
AGA2115, Placebo - Osteogenesis Imperfecta (OI)
Phase 2RecruitingAngitia Incorporated Limited802025-12-122026-11-04
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
ABSK061 - Achondroplasia
Phase 1 / Phase 2Not yet recruitingAbbisko Therapeutics Co, Ltd1102025-12-102025-12-22
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration - Achondroplasia
Phase 2RecruitingQED Therapeutics, a BridgeBio company772025-11-192026-07-13
An Interventional Study of Infigratinib in Children With Hypochondroplasia
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia
Phase 2 / Phase 3Enrolling by invitationQED Therapeutics, a BridgeBio company242025-04-222026-07-16
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg - Achondroplasia
Phase 2RecruitingTyra Biosciences, Inc922025-03-042026-10-01
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3RecruitingBicara Therapeutics6502025-01-282026-10-29
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Navepegritide, Placebo for navepegritide - Achondroplasia
Phase 2Active not recruitingAscendis Pharma A/S252024-12-102026-10-13
Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome
Etanercept, Placebo - SAPHO Syndrome
Phase 2 / Phase 3RecruitingNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland602024-09-042026-04-13
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial
Metformin Hydrochloride, betamethasone dipropionate, Pentoxifylline - Oral Submucous Fibrosis
Phase 1 / Phase 2CompletedZiauddin University302024-08-122025-05-02
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections - Achondroplasia
Phase 2Active not recruitingAscendis Pharma Growth Disorders A/S222024-07-262026-02-18
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Navepegritide, Placebo for Navepegritide - Achondroplasia
Phase 2RecruitingAscendis Pharma A/S722024-01-232026-04-08
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia
SAR442501 - Osteochondrodysplasia
Phase 2TerminatedSanofi162023-10-102026-06-25
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Losartan 25 milligram capsule, Placebo - Radiation Induced Fibrosis
Phase 2Active not recruitingShaw Cancer Center432023-08-172026-06-18
Radiographic Assessment of Bone Dimension Around Immediate Implants With FDBA and I-PRF vs FDBA Alone
i-PRF and FDBA - Bone Density Increased
Phase 2UnknownKrishnadevaraya College of Dental Sciences & Hospital202023-07-152024-07-30

Showing 20 of 83. Sign in to see all of them.

Narrower conditions

Achondroplasia (20)  ·  Camurati-Engelmann Syndrome (18)  ·  Osteogenesis Imperfecta (15)  ·  Bone Diseases (13)  ·  Dwarfism (13)  ·  Osteopetrosis (13)  ·  Musculoskeletal Diseases (11)  ·  Genetic Diseases, Inborn (8)  ·  Fibrous Dysplasia, Polyostotic (7)  ·  Mucopolysaccharidosis IV (7)  ·  Fibrous Dysplasia of Bone (6)  ·  Bone Diseases, Developmental (4)  ·  Anemia, Sickle Cell (3)  ·  Fibrosis (3)

Broader conditions

Bone Diseases, Developmental (79)  ·  Musculoskeletal Diseases (72)  ·  Bone Diseases (70)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (64)  ·  Genetic Diseases, Inborn (56)  ·  Skin and Connective Tissue Diseases (27)  ·  Connective Tissue Diseases (24)  ·  Endocrine System Diseases (16)  ·  Collagen Diseases (15)  ·  Metabolic Diseases (14)  ·  Neoplasms (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Neoplasms by Site (13)  ·  Osteosclerosis (13)

Interventions

vosoritide (6)  ·  infigratinib (5)  ·  setrusumab (5)  ·  Alemtuzumab (4)  ·  Busulfan (4)  ·  Zoledronic Acid (4)  ·  Cyclophosphamide (3)  ·  Denosumab (3)  ·  fludarabine (3)  ·  fludarabine phosphate (3)  ·  pembrolizumab (3)  ·  AP 1903 reagent (2)  ·  Cord Blood Stem Cell Transplantation (2)  ·  Losartan (2)  ·  Radiotherapy (2)

Sponsors

BioMarin Pharmaceutical (6)  ·  QED Therapeutics, a BridgeBio company (5)  ·  Ultragenyx Pharmaceutical Inc (5)  ·  National Institute of Dental and Craniofacial Research (NIDCR) (4)  ·  Ascendis Pharma A/S (3)  ·  Ascendis Pharma Growth Disorders A/S (3)  ·  Masonic Cancer Center, University of Minnesota (3)  ·  AstraZeneca (2)  ·  Bellicum Pharmaceuticals (2)  ·  Bicara Therapeutics (2)  ·  EMD Serono Research & Development Institute, Inc. (2)  ·  Eli Lilly and Company (2)  ·  Novartis Pharmaceuticals (2)  ·  Pfizer (2)  ·  University of Aarhus (2)

Countries

United States (53)  ·  United Kingdom (27)  ·  Australia (25)  ·  France (23)  ·  Canada (17)  ·  Spain (17)  ·  Italy (16)  ·  Germany (13)  ·  Denmark (12)  ·  Portugal (10)  ·  China (8)  ·  Japan (8)  ·  Belgium (7)  ·  Ireland (7)  ·  Poland (6)

Top investigators

Alison M Boyce, M.D. (3)  ·  Paul Orchard, MD (2)  ·  Alessandro M Gianni, MD (1)  ·  Amir Ali Hamidieh, MD (1)  ·  Andrea B Apolo, M.D. (1)  ·  Andrea Necchi, MD (1)  ·  Andrew Gilman, MD (1)  ·  Andrew M Scott, MBBS (1)

Results publications

PMID 38649657, PMID 31269546, PMID 32461347, PMID 42144862, PMID 22999294, PMID 24566706, PMID 24890385, PMID 25033066, PMID 28390753, PMID 29296761, PMID 30889272, PMID 31296256, PMID 31472446, PMID 31795071, PMID 32484386, PMID 32634238, PMID 32750127, PMID 33008091, PMID 33761804, PMID 34007848, PMID 34056870, PMID 34431071, PMID 35104665, PMID 35342457, PMID 35410255, PMID 36552855, PMID 36812441, PMID 36999533, PMID 37823031, PMID 37984383, PMID 38087967, PMID 38378678, PMID 38685585, PMID 38834319, PMID 38875119, PMID 39012717, PMID 39555818, PMID 41188357, PMID 41247754, PMID 41534675, PMID 41783511, PMID 42319555, PMID 42470570

NIH funding

2015 (2), 2016 (2), 2019 (2), 2005 (1), 2017 (1), 2018 (1), 2023 (1)